Table 1. Characteristics of studies included in the meta-analysis.
Cancer type | Year | First author | Country | Ethnicity | Source of control | Genotyping method | Polymorphism sites | Cases | Controls | HWE |
Cervical cancer | ||||||||||
2009 | Zucchini [52] | Maton Grosso do Sul, Brazil | African | PB | PCR-RFLP | Fas -670A>G | 91 | 176 | 0.545 | |
2008 | Tamandani [35] | Northern India | Asian | HB | PCR-RFLP | Fas -670A>G | 200 | 200 | 0.001 | |
2008 | Kang [4] | Korea | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 154 | 160 | 0.264, 0.233, 0.327 | |
2007 | Ivansson [53] | Sweden | Caucasian | PB | TaqMan | FasL -844C>T | 1284 | 280 | 0.738 | |
2006 | Ueda [34] | Japan | Asian | PB | PCR-RFLP | Fas -670A>G | 83 | 95 | 0.172 | |
2005 | Zoodsma [5] | Netherlands | Caucasian | PB | TaqMan | Fas -670A>G | 670 | 607 | 0.274 | |
2005 | Sun [6] | China | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 314 | 615 | 0.641, 0.304, 0.002 | |
2005 | Lai [7] | China | Asian | HB | TaqMan | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 318 | 318 | 0.736, 0.293, 0.920 | |
2004 | Dybikowska [8] | Poland | Caucasian | PB | PCR-RFLP | Fas -670A>G | 51 | 65 | 0.638 | |
2003 | Lai [9] | China | Asian | HB | PCR-RFLP | Fas -670A>G | 176 | 176 | 0.444 | |
Gastric cancer | ||||||||||
2012 | Zhang [10] | China | Asian | HB | PCR-RFLP | Fas -1377G>A, FasL -844C>T | 375 | 496 | 0.064, 0.112 | |
2011 | Liu [12] | China | Asian | PB | PCR-RFLP | Fas -1377G>A, FasL -844C>T | 344 | 324 | 0.424, 0.083 | |
2011 | Kupcinskas [11] | Mixed | Caucasian | PB | TaqMan | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 114 | 238 | 0.199, 0.492, 0.715 | |
2010 | Zhou [13] | China | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 262 | 524 | 0.133, 0.062, 0.899 | |
2009 | Wang [14] | China | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 332 | 324 | 0.806, 0.870, 0.554 | |
2008 | Hsu [15] | China | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 86 | 101 | 0.736, 0.914, 0.612 | |
2006 | Ikehara [54] | Japan | Asian | PB | PCR-CTPP | Fas -670A>G | 271 | 271 | 0.504 | |
Breast cancer | ||||||||||
2013 | Hashemi [16] | Iranian | Caucasian | PB | T-ARMS-PCR | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 134 | 152 | 0.045, 0.000, 0.183 | |
2012 | Wang [17] | China | Asian | HB | PCR-RFLP | Fas -1377G>A, FasL -844C>T | 375 | 496 | 0.064, 0.112 | |
2012 | Mahfoudh [18] | Tunisia | African | PB | PCR-RFLP | FasL -844C>T | 438 | 332 | 0.334 | |
2007 | Crew [19] | America | Caucasian | PB | TaqMan | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 1051 | 1101 | 0.754, 0.069, 0.602 | |
2007 | Zhang [20] | China | Asian | HB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 836 | 834 | 0.797, 0.700, 0.110 | |
2004 | Krippl [21] | Austria | Caucasian | PB | TaqMan | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 499 | 495 | 0.924, 0.610, 0.418 | |
Lung cancer | ||||||||||
2008 | Ter-Minassian [22] | America | Caucasian | HB | TaqMan | Fas -1377G>A, FasL -844C>T | 2174 | 1497 | 0.751, 0.254 | |
2007 | Gormus [23] | Turkey | Caucasian | PB | PCR-RFLP | Fas -1377G>A | 94 | 50 | 0.000 | |
2006 | Park [24] | Korea | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 582 | 582 | 0.132, 0.024, 0.570 | |
2005 | Zhang [25] | China | Asian | PB | PCR-RFLP | Fas -1377G>A, FasL -844C>T | 1000 | 1270 | 0.046, 0.180 | |
2003 | Wang [55] | America | Mixed | PB | PCR-RFLP | Fas -670A>G | 68 | 74 | 0.481 | |
Esophageal cancer | ||||||||||
2011 | Bye [32] | Eastern or Western Cape | African | PB | TaqMan | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 343 | 466 | 0.027, 0.670, 0.097 | |
2011 | Bye [32] | Western Cape | Mixed | PB | TaqMan | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 195 | 420 | 0.170, 0.469, 0.741 | |
2007 | Jain [56] | Northern India | Asian | PB | PCR-RFLP | Fas -670A>G | 151 | 201 | 0.140 | |
2003 | Sun [57] | China | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 588 | 648 | 0.130, 0.218, 0.061 | |
Skin cancer | ||||||||||
2010 | Qureshi [58] | Britain | Caucasian | PB | NA | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 779 | 842 | 0.210, 0.916, 0.427 | |
2007 | Zhang [59] | Sweden | Caucasian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 229 | 351 | 0.380, 0.009, 0.609 | |
2006 | Li [60] | America | Caucasian | HB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 602 | 603 | 0.453, 0.951, 0.071 | |
2001 | Nelson [61] | America | Caucasian | PB | PCR-RFLP | Fas -670A>G | 776 | 435 | 0.117 | |
Ovarian cancer | ||||||||||
2012 | Li [62] | China | Asian | PB | Allele-specific multiple ligase detection | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 342 | 344 | 0.357, 0.972, 0.547 | |
2007 | Gormus [63] | Turkey | Caucasian | PB | PCR-RFLP | Fas -1377G>A, FasL -844C>T | 47 | 41 | 0.272, 0.678 | |
2006 | Ueda [34] | Japan | Asian | PB | PCR-RFLP | Fas -670A>G | 68 | 95 | 0.172 | |
Prostate cancer | ||||||||||
2012 | Mandal [51] | Northern India | Asian | HB | PCR-RFLP | Fas -670A>G, Fas -1377G>A | 192 | 224 | 0.296, 0.035 | |
2011 | Shao [38] | China | Asian | HB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 602 | 703 | 0.579, 0.099, 0.801 | |
2008 | Lima [64] | Portugal | Caucasian | PB | PCR-RFLP | Fas -670A>G | 657 | 247 | 0.365 | |
Nasopharyngeal cancer | ||||||||||
2010 | Cao [65] | China | Asian | PB | PCR-RFLP | Fas -1377G>A, FasL -844C>T | 576 | 608 | 0.984, 0.015 | |
2010 | Zhu [66] | China | Asian | PB | PCR-RFLP | Fas -670A>G | 237 | 264 | 0.478 | |
2006 | Jrad [37] | Tunisia | African | PB | PCR-RFLP | Fas -670A>G | 170 | 224 | 0.585 | |
Bladder cancer | ||||||||||
2010 | Gangwar [67] | Northern India | Asian | PB | PCR-RFLP | Fas -670A>G | 212 | 250 | 0.384 | |
2006 | Li [68] | China | Asian | HB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 216 | 252 | 0.409, 0.970, 0.234 | |
Other cancers | ||||||||||
2010 | Zhu [69] | China | Asian | HB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 353 | 365 | 0.831, 0.777, 0.278 | |
2010 | Wang [70] | China | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 294 | 333 | 0.034, 0.628, 0.271 | |
2008 | Yang [39] | China | Asian | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 397 | 907 | 0.653, 0.062, 0.986 | |
2007 | Koshkina [71] | America | Mixed | PB | PCR-RFLP | Fas -670A>G, Fas -1377G>A | 123 | 510 | 0.786, 0.210 | |
2007 | Erdogan [72] | Turkey | Caucasian | HB | PCR-RFLP | Fas -670A>G, FasL -844C>T | 45 | 100 | 0.812, 0.727 | |
2007 | Hoa [33] | America | Mixed | HB | PCR-RFLP | Fas -1377G>A | 279 | 510 | 0.210 | |
2007 | Hob [33] | America | Mixed | HB | PCR-RFLP | Fas -1377G>A | 154 | 510 | 0.210 | |
2006 | Zhang [36] | America | Caucasian | HB | PCR-RFLP | Fas -670A>G, Fas -1377G>A, FasL -844C>T | 721 | 1234 | 0.481, 0.268, 0.411 | |
2006 | Ueda [34] | Japan | Asian | PB | PCR-RFLP | Fas -670A>G | 108 | 95 | 0.172 |
The Ho(a) investigated thyroid cancer, and the Ho(b) investigated salivary gland cancer.
PB: population based; HB: hospital based; T-ARMS-PCR:tetra-primeramplification refractory mutation system PCR; PCR-RFLP: restriction fragment length polymorphism; HWE: Hardy-Weinberg equilibrium.